HealthyNCT05517122
Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults
A study testing Nicotinamide (NAM), Nicotinamide Riboside (NR) and Nicotinamide Mono Nucleotide (NMN) in people with Healthy, run by Société des Produits Nestlé (SPN) at 1 site in Switzerland.
Trial summary
Nicotinamide adenine dinucleotide (NAD) is a coenzyme playing a central role in human metabolic pathways. A recognized approach to increase NAD level is through oral supplementation of its precursors promoting NAD synthesis in vivo. NAD precursors exist in multiple forms. Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Nicotinamide (NAM), Nicotinamide Riboside (NR) and Nicotinamide Mono Nucleotide (NMN)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 68 participants
- Where
- 1 siteSwitzerland
- Study dates
- 12 Jul 2022to 24 Nov 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male and female aged 18-50 years, inclusive, at enrolment
- Body mass index (BMI) between 18.5 to 27.0 kg/m².
- Able to understand and to sign a written informed consent prior to study enrolment.
- Willing and able to comply with the requirements for participation in this study.
Who cannot join
- Known history of allergy or intolerance to the investigational products.
- Any chronic medical condition and/or history of significant medical condition, which in the opinion of the site physician/ investigator may risk participant wellbeing/ safety, impede participant compliance with study procedures or ability to complete the study and/ or could confound the primary objectives of the study.
- Any acute illness or any recent medical intervention including vaccination within 14 days before the first dose of investigational product.
- Female participants who are pregnant or intending to become pregnant, lactating and/or breastfeeding. Women of childbearing potential who are not currently using medically effective forms of contraception.
- Use of prescription drugs known to potentially interact with NAD precursors within 14 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
- Use of multivitamin/ multimineral supplements, NAD+ precursor supplementation (e.g., niacin, nicotinic acid or niacinamide), L-tryptophan supplementation and/ or any over-the- counter (OTC) medication promoting "healthy aging" or "anti-aging" or "longevity" up to 30 days before first dose of investigational product.
Show all 12Show fewer
- On a self-restricted diet, controlled diet or special therapeutic diet up to 30 days before first dose of investigational product.
- Average alcohol consumption greater than 2 standard drinks per day over a week for males, and greater than 1 standard drink per day over a week for females. One standard drink contains 10-12 g of ethanol. Examples of standard drinks are one beer can (300 ml), one glass of wine (100 ml) or one glass of schnaps (30 ml).
- Current smoker (e.g., cigarette, tobacco, cannabis) who exceeds 5 cigarettes per week.
- Performing shift work or trans-meridian travel greater than two time zones within 14 days prior to the first dose of investigational product.
- Currently participating in another research study.
- Family or hierarchical relationships with the Clinical Innovation Lab (CIL) team.
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Nestlé Clinical Innovation Lab
Lausanne, Canton of Vaud, 1000
About this study
Nicotinamide adenine dinucleotide (NAD) is a coenzyme playing a central role in human metabolic pathways. A recognized approach to increase NAD level is through oral supplementation of its precursors promoting NAD synthesis in vivo. NAD precursors exist in multiple forms. However, it is unclear how the various precursors compare in their ability to increase NAD levels in human blood. The purpose of this study is to compare the effect of 3 NAD precursors on whole blood NAD metabolome.
- Conditions
- Healthy
- Being tested
- Nicotinamide (NAM), Nicotinamide Riboside (NR), Nicotinamide Mono Nucleotide (NMN), Microcrystalline cellulose
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nicotinamide (NAM)Dietary supplement
500 mg a day
Nicotinamide Riboside (NR)Dietary supplement
1000 mg a day
Nicotinamide Mono Nucleotide (NMN)Dietary supplement
1000 mg a day
Microcrystalline celluloseDietary supplement
500 mg a day
| Study group | Role | What they receive |
|---|---|---|
| Nicotinamide (NAM) | Experimental | Not described Receives: Dietary Supplement: Nicotinamide (NAM) |
| Nicotinamide Riboside (NR) | Experimental | Not described Receives: Dietary Supplement: Nicotinamide Riboside (NR) |
| Nicotinamide Mono Nucleotide (NMN) | Experimental | Not described Receives: Dietary Supplement: Nicotinamide Mono Nucleotide (NMN) |
| Microcrystalline cellulose | Placebo comparator | Not described Receives: Dietary Supplement: Microcrystalline cellulose |
What is being measured
The primary outcome is the main question the study is designed to answer.
Determine the extent of increase in NAD+ level in whole blood, for each NAD+ precursor (NAM, NR and NMN) compared to placebo
Measure the changes in whole blood NAD+ level interventions vs placebo: NAM vs placebo, NR vs placebo, NMN versus placebo by quantitative liquid chromatography-mass spectroscopy
Measured: at Day 14
Compare the extent of increase in NAD+ level in whole blood across the 3 NAD+ precursors (NAM, NR and NMN)
Measure the changes in whole blood NAD+ level across interventions: NAM vs NR, NAM vs NMN, NR vs NMN by quantitative liquid chromatography-mass spectroscopy
Measured: at Day 14
Secondary outcomes (2)
Determine the extent the NAD+ precursors(NAM, NR and NMN) affect the NAD metabolome in whole blood compared to placebo
Measure the change in whole blood NAD+ metabolites iAUC (reported as microM*h) and Cmax (microM) by quantitative liquid chromatography-mass spectroscopy
Measured: over 4 hours at Day 1 and at Day 14.
Compare the extent the NAD+ precursors (NAM, NR and NMN) affect the NAD+ metabolome in whole blood.
Measure the change in whole blood NAD+ metabolites iAUC (reported as microM*h) and Cmax (microM) determined by quantitative liquid chromatography-mass spectroscopy
Measured: over 4 hours at Day 1 and at Day 14.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Aug 2022
- Study start12 Jul 2022
- Primary completion24 Nov 2022
- Study completion24 Nov 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Société des Produits Nestlé (SPN)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 68 participants (actual)
Sponsor and investigators
- Lead sponsor
- Société des Produits Nestlé (SPN)
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05517122
- Sponsor's protocol ID
- 2201NR
- Status last verified
- Apr 2025
- First submitted
- 4 Jul 2022
- Last updated
- 24 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Christen S, Redeuil K, Goulet L, Giner MP, Breton I, Rota R, Frezal A, Nazari A, Van den Abbeele P, Godin JP, Nutten S, Cuenoud B. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026 Jan;8(1):62-73. doi: 10.1038/s42255-025-01421-8. Epub 2026 Jan 15.
PubMed 41540253
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults
- ClinicalTrials.gov ID
- NCT05517122
- Acronym / sponsor ID
- 2201NR
- Conditions
- Healthy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 68 participants (actual)
- Lead sponsor
- Société des Produits Nestlé (SPN)Industry (pharma, biotech, devices)
- Study start
- 12 Jul 2022 (actual)
- Primary completion
- 24 Nov 2022 (actual)
- Study completion
- 24 Nov 2022 (actual)
- First posted
- 26 Aug 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Nicotinamide adenine dinucleotide (NAD) is a coenzyme playing a central role in human metabolic pathways. A recognized approach to increase NAD level is through oral supplementation of its precursors promoting NAD synthesis in vivo. NAD precursors exist in multiple forms. However, it is unclear how the various precursors compare in their ability to increase NAD levels in human blood. The purpose of this study is to compare the effect of 3 NAD precursors on whole blood NAD metabolome.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Nicotinamide (NAM) | Experimental | Dietary Supplement: Nicotinamide (NAM) |
| Nicotinamide Riboside (NR) | Experimental | Dietary Supplement: Nicotinamide Riboside (NR) |
| Nicotinamide Mono Nucleotide (NMN) | Experimental | Dietary Supplement: Nicotinamide Mono Nucleotide (NMN) |
| Microcrystalline cellulose | Placebo comparator | Dietary Supplement: Microcrystalline cellulose |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Healthy male and female aged 18-50 years, inclusive, at enrolment
- Body mass index (BMI) between 18.5 to 27.0 kg/m².
- Able to understand and to sign a written informed consent prior to study enrolment.
- Willing and able to comply with the requirements for participation in this study.
Key exclusion criteria (12 listed)
- Known history of allergy or intolerance to the investigational products.
- Any chronic medical condition and/or history of significant medical condition, which in the opinion of the site physician/ investigator may risk participant wellbeing/ safety, impede participant compliance with study procedures or ability to complete the study and/ or could confound the primary objectives of the study.
- Any acute illness or any recent medical intervention including vaccination within 14 days before the first dose of investigational product.
- Female participants who are pregnant or intending to become pregnant, lactating and/or breastfeeding. Women of childbearing potential who are not currently using medically effective forms of contraception.
- Use of prescription drugs known to potentially interact with NAD precursors within 14 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nicotinamide (NAM)500 mg a day | Dietary supplement | Nicotinamide (NAM) |
| Nicotinamide Riboside (NR)1000 mg a day | Dietary supplement | Nicotinamide Riboside (NR) |
| Nicotinamide Mono Nucleotide (NMN)1000 mg a day | Dietary supplement | Nicotinamide Mono Nucleotide (NMN) |
| Microcrystalline cellulose500 mg a day | Dietary supplement | Microcrystalline cellulose |
Primary outcome
Determine the extent of increase in NAD+ level in whole blood, for each NAD+ precursor (NAM, NR and NMN) compared to placebo
Time frame: at Day 14
Measure the changes in whole blood NAD+ level interventions vs placebo: NAM vs placebo, NR vs placebo, NMN versus placebo by quantitative liquid chromatography-mass spectroscopy
Compare the extent of increase in NAD+ level in whole blood across the 3 NAD+ precursors (NAM, NR and NMN)
Time frame: at Day 14
Measure the changes in whole blood NAD+ level across interventions: NAM vs NR, NAM vs NMN, NR vs NMN by quantitative liquid chromatography-mass spectroscopy
2 secondary outcomes
Determine the extent the NAD+ precursors(NAM, NR and NMN) affect the NAD metabolome in whole blood compared to placebo
Time frame: over 4 hours at Day 1 and at Day 14.
Compare the extent the NAD+ precursors (NAM, NR and NMN) affect the NAD+ metabolome in whole blood.
Time frame: over 4 hours at Day 1 and at Day 14.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2025.
- Derived from this study: PubMed 41540253Christen S, Redeuil K, Goulet L, Giner MP, Breton I, Rota R, Frezal A, Nazari A, Van den Abbeele P, Godin JP, Nutten S, Cuenoud B. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026 Jan;8(1):62-73. doi: 10.1038/s42255-025-01421-8. Epub 2026 Jan 15.
- Individual participant dataSharing planned: Undecided
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nicotinamide (NAM), Nicotinamide Riboside (NR) and Nicotinamide Mono Nucleotide (NMN) in people with Healthy, run by Société des Produits Nestlé (SPN) at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Determine the extent of increase in NAD+ level in whole blood, for each NAD+ precursor (NAM, NR and NMN) compared to placebo (time frame: at Day 14). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05517122, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2025.